Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 3
Submit an article Journal homepage
303
Views
1
CrossRef citations to date
0
Altmetric
Obesity

Liraglutide for weight management: benefits and risks

Brian TomlinsonResearch Center for Translational Medicine, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai, China; ;Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong;
,
Miao HuDepartment of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong;
,
Yuzhen ZhangResearch Center for Translational Medicine, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai, China;
,
Paul ChanDivision of Cardiology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan;
&
Zhong-Min LiuDepartment of Cardiac Surgery, Shanghai East Hospital, Tongji University, Shanghai, ChinaCorrespondence[email protected]
Pages 537-539 | Received 10 Nov 2016, Accepted 08 Dec 2016, Published online: 04 Jan 2017

References

  • Bays H, Pi-Sunyer X, Uddén Hemmingsson J, et al. Liraglutide 3.0 mg for weight management: Weight-loss dependent and independent effects. Curr Med Res Opin 2016
  • Tomlinson B, Hu M, Zhang Y, et al. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs 2016;25:145-58
  • Tomlinson B, Hu M, Zhang Y, et al. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs 2016;25:1167-1179
  • Tomlinson B, Hu M, Zhang Y, et al. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opin Drug Metab Toxicol 2016. DOI: 10.1080/17425255.2016.1234608.
  • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22
  • Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-54
  • Russo GT, Labate AM, Giandalia A, et al. Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest 2015;38:81-9
  • Mulligan CM, Harper R, Harding J, et al. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther 2013;4:147-51
  • Ostawal A, Mocevic E, Kragh N, Xu W. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther 2016;7:411-38
  • Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22
  • James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17
  • Palatini P, Rosei EA, Casiglia E, et al. Management of the hypertensive patient with elevated heart rate: statement of the Second Consensus Conference endorsed by the European Society of Hypertension. J Hypertens 2016;34:813-21
  • Tomlinson B, Sritara P, Lopez E, et al. Hypertension and elevated heart rate: focus on the Asia Pacific region. J Hypertens 2016;34:2330-2
  • Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia 2012;55:1283-90
  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
  • Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016;37:1526-34
  • Tomlinson B, Hu M, Zhang Y, et al. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2016. DOI: 10.1080/17425255.2017.1258401.
  • Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring) 2016;24:2278-88

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.